<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04697602</url>
  </required_header>
  <id_info>
    <org_study_id>202009131MIND</org_study_id>
    <nct_id>NCT04697602</nct_id>
  </id_info>
  <brief_title>Low-dose Colchicine With or Without Stepwise Dose Titration of Febuxostat for Flare Prophylaxis in Gout</brief_title>
  <official_title>Low-dose Colchicine With or Without Stepwise Dose Titration of Febuxostat for Flare Prophylaxis in Patients With Gout and Hyperuricemia During the Initial Phase of Urate-lowering Therapy: an Open-label Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital, Yun-Lin Branch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the incidence rate of gout flare for subjects with&#xD;
      gout and hyperuricemia treated by two different starting doses of febuxostat.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized open-label study comparing dose titration group (stepwise dose&#xD;
      titration of febuxostat and low-dose colchicine) and standard treatment group (fixed dose&#xD;
      febuxostat and low-dose colchicine) in the subjects with gout and hyperuricemia. The&#xD;
      incidence rate of gout flare will be compared between two groups during the first 12 week of&#xD;
      febuxostat treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence rate of gout flare during the first 12 weeks.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The percentage of the patients suffered from gout flare during the first 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of gout flares per patient during the first 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of gout flares per patient during the first 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of gout flares per patient during the second 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of gout flares per patient during the second 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients with serum urate &lt;6.0mg/dL in 12, 24 weeks</measure>
    <time_frame>12, 24 weeks</time_frame>
    <description>The percentage of patients with serum urate &lt;6.0mg/dL in 12, 24 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Dose titration group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stepwise dose titration of febuxostat and low-dose colchicine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fixed dose febuxostat and low-dose colchicine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stepwise dose titration of febuxostat and low-dose colchicine</intervention_name>
    <description>Febuxostat 10 mg, orally, once daily, in week 1-4 Febuxostat 20 mg, orally, once daily, in week 5-8 Febuxostat 40 mg, orally, once daily, in week 9-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12</description>
    <arm_group_label>Dose titration group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed dose febuxostat and low-dose colchicine</intervention_name>
    <description>Febuxostat 40 mg, orally, once daily, in week 1-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12</description>
    <arm_group_label>Standard treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Ages Eligible for Study: more than 20 years&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Hyperuricemia (serum urate ≥7.0 mg/dL and gout by 1977 American College of&#xD;
             Rheumatology Criteria&#xD;
&#xD;
          2. Acute gout attack during the last 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute gout attack in the last 2 weeks&#xD;
&#xD;
          2. Urate-lowering therapy in the last 4 weeks&#xD;
&#xD;
          3. Secondary hyperuricemia&#xD;
&#xD;
          4. Creatinine ≥2.0 mg/dL&#xD;
&#xD;
          5. AST or ALT ≥2x upper limits of normal&#xD;
&#xD;
          6. Heart failure (NYHA III-IV)&#xD;
&#xD;
          7. Hypersensitivity to colchicine, NSAID or febuxostat&#xD;
&#xD;
          8. Use of NSAID, glucocorticoid, cyclosporine, clarithromycin, mercaptopurine,&#xD;
             azathioprine, pyrazinamide, ethambutol, chemotherapy, tacrolimus, losartan, and&#xD;
             fenofibrate&#xD;
&#xD;
          9. Inability to comply with the protocol requirements&#xD;
&#xD;
         10. The judgement of the investigator that the patient was not an appropriate candidate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Min Huang</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital, Yun-Lin Branch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi-Min Huang</last_name>
    <phone>0972655455</phone>
    <email>zeamayschang@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yi-Min Huang</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YIMIN HUANG</last_name>
      <email>zeamayschang@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 24, 2021</last_update_submitted>
  <last_update_submitted_qc>January 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gout,febuxostat,flare prophylaxis,stepwise dose titration,colchicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

